Item Type | Name |
Concept
|
Chemoradiotherapy, Adjuvant
|
Concept
|
Chemoradiotherapy
|
Academic Article
|
Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer.
|
Academic Article
|
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.
|
Academic Article
|
Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure.
|
Academic Article
|
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
|
Academic Article
|
Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy.
|
Academic Article
|
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck.
|
Academic Article
|
Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
|
Academic Article
|
Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions.
|
Academic Article
|
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.
|
Academic Article
|
Concurrent chemoradiotherapy for head and neck cancer.
|
Academic Article
|
Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer.
|
Academic Article
|
High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial.
|
Academic Article
|
Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue.
|
Academic Article
|
Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer.
|
Academic Article
|
Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer.
|
Academic Article
|
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation.
|
Academic Article
|
Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck.
|
Academic Article
|
Chemoradiation for patients with large-volume laryngeal cancers.
|
Academic Article
|
Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy.
|
Academic Article
|
Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies.
|
Academic Article
|
Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy.
|
Academic Article
|
Neck response to chemoradiotherapy: complete radiographic response correlates with pathologic complete response in locoregionally advanced head and neck cancer.
|
Academic Article
|
Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction.
|
Academic Article
|
Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer.
|
Academic Article
|
Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431.
|
Academic Article
|
Chemoradiotherapy for locally advanced head and neck cancer.
|
Academic Article
|
Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.
|
Academic Article
|
Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002.
|
Academic Article
|
Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer.
|
Academic Article
|
Non-small-cell lung cancer: then and now.
|
Academic Article
|
Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.
|
Academic Article
|
Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma.
|
Academic Article
|
A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.
|
Academic Article
|
New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer.
|
Academic Article
|
Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105.
|
Academic Article
|
A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531.
|
Academic Article
|
Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206.
|
Academic Article
|
Induction chemotherapy followed by concomitant chemoradiotherapy for non-small cell lung cancer.
|
Academic Article
|
Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer.
|
Academic Article
|
Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy.
|
Academic Article
|
Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904.
|
Academic Article
|
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
|
Academic Article
|
A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904.
|
Academic Article
|
EGFR-based bioradiotherapy in SCCHN.
|
Academic Article
|
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.
|
Academic Article
|
Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
|
Academic Article
|
Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.
|
Academic Article
|
Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck.
|
Academic Article
|
Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer.
|
Academic Article
|
Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience.
|
Academic Article
|
The Impact of Staging by Positron-Emission Tomography on Overall Survival and Progression-Free Survival in Patients With Locally Advanced NSCLC.
|
Academic Article
|
A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients.
|
Academic Article
|
Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC.
|
Academic Article
|
Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer.
|
Academic Article
|
Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis.
|
Academic Article
|
Beyond PACIFIC: Uncharted Waters.
|
Academic Article
|
Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer.
|
Academic Article
|
Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience.
|
Academic Article
|
All-trans retinoic acid overcomes solid tumor radioresistance by inducing inflammatory macrophages.
|
Academic Article
|
Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment.
|
Academic Article
|
Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study.
|